BridgeBio Pharma BBIO Change in Deferred Revenue
Change in Deferred Revenue at other companies
Other financials
Where this comes from
Reported directly by BridgeBio Pharma in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInDeferredRevenue.
The official record: BridgeBio Pharma’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about BridgeBio Pharma's change in deferred revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BridgeBio Pharma's change in deferred revenue?
- BridgeBio Pharma (BBIO) reported change in deferred revenue of -$2.38M in Q1 2026.
- How has BridgeBio Pharma's change in deferred revenue changed year-over-year?
- BridgeBio Pharma's change in deferred revenue increased by 7.5% year-over-year, from -$2.57M to -$2.38M.
- What does change in deferred revenue mean?
- The net change in payments received from customers for services not yet provided.
- How do you interpret change in deferred revenue?
- An increase suggests growing customer demand or favorable billing terms, while a decrease may indicate revenue recognition outpacing new bookings.
- How does change in deferred revenue compare across companies?
- Common in SaaS and biopharma licensing; peers typically show positive trends during high-growth commercialization phases.